论文部分内容阅读
AMSA,一种新的细胞毒药物,是台成的吖啶类化合物,临床前试验证实它具有和DNA分子结合、抑制DNA合成的特性,因而具有抗瘤作用。1978年4月～1979年8月间作者用AMSA治疗62例成人急性白血病复治病例(男43例,女19例,中位数年龄32岁,47例小于50岁)。其中急粒41例,急淋14例,未分化型6例,慢粒1例,所有病例均曾用过1～5次的由常用药物组成的化疗方案,包括DNR、VCR、Ara-C、Pred
AMSA, a new cytotoxic drug, is an acridine compound formed in Taiwan. Preclinical tests have demonstrated that it has the property of binding to DNA molecules and inhibiting DNA synthesis, and thus has an anti-tumor effect. From April 1978 to August 1979, the authors treated 62 adult acute leukemia retreatment cases (43 males and 19 females, with a median age of 32 years and 47 cases less than 50 years) treated with AMSA. There were 41 acute granules, 14 acute leaching, 6 undifferentiated, and 1 chronic granulocytic. In all cases, 1 to 5 chemotherapeutic regimens consisting of commonly used drugs were used, including DNR, VCR, and Ara-C. Pred